Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,46.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,55.0,1.0,=,0.8
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,98.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,194.0,1.0,=,0.5
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,133.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,101.0,1.0,=,1.3
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,500.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,130.0,1.0,=,3.8
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,333.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,257.0,1.0,=,1.3
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,244.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,205.0,1.0,=,1.2
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,268.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,308.0,1.0,=,0.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,251.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,377.0,1.0,=,0.7
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,298.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,648.0,1.0,=,0.5
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,38.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,45.0,1.0,=,0.8